Revenue: As of FY2025, the actual value is USD 319.71 K, beating the estimate of USD 249 K.EPS: As of FY2025, the actual value is USD -4.86.EBIT: As of FY2025, the actual value is USD -10.31 M.<h4>Segment Revenue</h4>Vyome Holdings, Inc.’s total revenue for the year ended December 31, 2025, was $319,714, an increase from $256,944 in 2024, with all revenue attributed to the pharmaceutical segment .Pharmaceutical Segment Revenue Breakdown: Ingredient sales under Luliconazole Agreement were $0 in 2025, down from $75,147 in 2024 . Service fees for arrangements for the sale of dandruff products were $116,900 in 2025, up from $0 in 2024, although this arrangement was terminated in December 2024 . Royalty income related to product sales was $28,169 in 2025, a decrease from $47,402 in 2024 . Licensing and milestone fees – Luliconazole amounted to $174,645 in 2025, an increase from $134,395 in 2024 .<h4>Operational Metrics</h4><ul><li>Gross Profit was $218,771 in 2025, an increase from $194,970 in 2024 .</li><li>Research and Development Expenses significantly increased to $588,258 in 2025 from $285,391 in 2024, primarily due to resuming R&amp;D after the Merger with new funds .</li><li>Depreciation and Amortization decreased to $11,985 in 2025 from $17,347 in 2024 .</li><li>General and Administrative Expenses were substantially higher at $2,365,565 in 2025 compared to $898,572 in 2024, mainly due to increased legal, accounting, auditing, and related professional fees for the Merger, and $577,128 in stock-based compensation .</li><li>Transactional Fees totaled $7,705,533 in 2025, comprising approximately $5.9 million in fair value of shares issued to advisors and $1.8 million in cash paid to advisors and professionals related to the Merger, with no transactional fees in 2024 .</li><li>Total Operating Expenses were $10,671,341 in 2025, up from $1,201,310 in 2024 .</li><li>Loss from Operations was -$10,452,570 in 2025, compared to -$1,006,340 in 2024 .</li><li>Interest Expense was -$146,641 in 2025, a decrease from -$206,004 in 2024, driven by the conversion of convertible notes and debt in August 2025 .</li><li>Fair Value Adjustment was $30,511 (favorable) in 2025, compared to -$238,931 (unfavorable) in 2024, reflecting the probability and timing of the Merger completion, with no further adjustments after August 2025 .</li><li>Net Loss was -$10,477,713 in 2025, compared to -$1,447,461 in 2024 .</li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was -$3,748,853 in 2025, an increase from -$614,136 in 2024 .</li><li>Net cash provided by investing activities was $0 in 2025, compared to $315 in 2024 .</li><li>Net cash provided by financing activities was $8,654,976 in 2025, a significant increase from $697,951 in 2024 .</li><li>Net increase in cash and cash equivalents was $4,880,429 in 2025, compared to $85,257 in 2024 .</li></ul><h4>Outlook / Guidance</h4>Vyome Holdings, Inc. expects to discuss a pivotal trial study design for VT-1953 with the FDA in Q2 2026, with primary endpoint readouts anticipated in late 2026 . The company projects significant losses for the foreseeable future and plans to initiate IND-enabling studies for VT-1908 in Q4 2025 . Existing cash and cash equivalents are expected to cover operating expenses and capital expenditure requirements until June 2027, but additional capital will be necessary for future operations .

Vyome | 10-K: FY2025 Revenue Beats Estimate at USD 319.71 K